[PDF] Top 20 Target selection for CAR-T therapy
Has 10000 "Target selection for CAR-T therapy" found on our website. Below are the top 20 most common "Target selection for CAR-T therapy".
Target selection for CAR-T therapy
... The CAR-T cells we made generally possess unitary specificity, which means only one target could be recog- ...of CAR-T cells, espe- cially for the treatment of highly heterogeneous ... See full document
9
State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019
... to target the IL2-inducible T-cell kinase (ITK), which orients T cells towards a Th1 cytokine secretion profile ...autologous T cells (before and after transduction) from a Th2 profile to a ... See full document
6
Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
... the target antigen of the T cell-directed therapy, or the symptom onset ...anti-cytokine therapy because clinical judgment is required to apply therapeutic intervention based on individual ... See full document
12
CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation
... MUC1-targeted T cells retained effector function in the suppressive tumor microenvironment, we paired our CAR with a chimeric receptor designed to harness and invert the inhibitory effects of tumor-produced ... See full document
13
Critical factors in chimeric antigen receptor-modified T-cell (CAR-T) therapy for solid tumors
... The selection of an optimal T-cell subset as the material for preparing CAR-T can enhance the effect of the ...endogenous T cells, after receiving the pMHC signal, naive T cells ... See full document
12
CAR-T cell therapy: a potential new strategy against prostate cancer
... CD19-directed CAR-T cells for the treat- ment of relapsed/refractory pediatric and young-adult diffuse large B cell lymphoma (DLBCL), also sparking off research into solid ...same target antigen for ... See full document
11
Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies
... for T cell ...of T cells ...and CAR-T cell persistence [126]. Fourth-generation CARs called T cell redirected for antigen-unrestricted cytokine-initiated killing (TRUCKs) encode genes ... See full document
20
CAR-T cell therapy in neuro-oncology: applications and toxicity
... modified CAR-T cell redirected to target MUC1 positive tumors in patients with recurrent/relapsed malignant glioma ...anti-EGFRvIII CAR in patients with malignant glioma who are positive for ... See full document
12
Engineering switchable and programmable universal CARs for CAR T therapy
... However, the current modular design of the switching molecules relies on adding exogenous sequences/epi- topes. This process requires complicated recombinant engineering processes and also known target sequences. ... See full document
9
CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia
... The autologous material from leukapheresis is then shipped to a manufacturing facility. Novartis has currently two facilities to produce CTL019, one in Morris Plains, NJ, USA and the other in Leipzig, Germany. UPenn ... See full document
14
Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy
... of CAR-T cell therapy [28, 29, 34, 42, 69– 71]. These CAR-T cells trafficking to cerebrospinal fluid (CSF) are able to eradicate the CNS malignancy effi- ciently in a subset of patients ... See full document
10
CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery
... + T cells were modified utilizing a len- tiviral vector system to express a chimeric antigen recep- tor (CAR) targeting myelin oligodendrocyte glycoprotein (MOG) in trans with the murine FoxP3 gene that ... See full document
12
Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin’s lymphoma
... the T cells are activated, proliferation of T cells and cytotoxic granule secretion ensues, which leads to antitumor activity and lysis of tumor ...limit T-cell activa- tion and cause T-cell ... See full document
11
Treatment of malignant pleural mesothelioma by fibroblast activation protein specific re directed T cells
... immune therapy could be ...directed T cells as a new option for treatment of ...[13]. T cells expressing anti-FAP CARs at high level were generated by standard procedures and these re-directed ... See full document
11
Engineering CAR-T cells
... intracellular T cell activation domain of CD3ζ [1]. CAR-T cell therapy is designed to redirect a patient’s or donor’s T cells to specifically target and destroy tumor ...of ... See full document
6
<p>Chimeric antigen receptor (CAR) T-cell therapy as a treatment option for patients with B-cell lymphomas: perspectives on the therapeutic potential of Axicabtagene ciloleucel</p>
... of CAR T-cells through the brain blood barrier may contribute to these ...redirected T-cell therapies, also observed in Blinatumomab and other CD19-directed bispeci fi c ...other CAR and ... See full document
12
Target discovery for T cell therapy: next steps to advance Immunotherapies
... Off- Target Reactivity”. Adoptive T cell therapy (ACT) with gene-modified T cells expressing exogenous TCRs is emerging as a highly promising strategy for the treat- ment of many types of ... See full document
5
The functional verification of EGFR-CAR T-cells targeted to hypopharyngeal squamous cell carcinoma
... receptor T-cells (CART) therapy is a type of adoptive cellular ...the T-cells of an affected patient, introduce the coding gene of an antibody-like protein by genetic engineering technology into ... See full document
7
Treating Cancer With Engineered T Cell Therapies: Murine and Canine Models of Safety and Efficacy
... non-regulatable CAR T cell-based strategies targeting ...as T cells (Chames et ...antibody therapy (Herceptin) has not shown adverse events, but treatment with a relatively high dose of a ... See full document
197
A good response of refractory mantel cell lymphoma to haploidentical CAR T cell therapy after failure of autologous CAR T cell therapy
... of CAR T cell therapy is multiple molecular targeted therapies includ- ing rituximab, ibrutinib and ...of CAR T ...CD20-targeted CAR T cells is preserved in vivo at ... See full document
7
Related subjects